Moderately to Severely Active Ulcerative Colitis Clinical Trials in New York, New York
2 recruitingNew York, New York
Showing 1–2 of 2 trials
Recruiting
Phase 3
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche100 enrolled9 locationsNCT07158242
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche350 enrolled198 locationsNCT06588855